查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1170449

美國東南部的腎臟病市場:～2027年

Southeast Us Renal Disease Market Research Report Forecast to 2027
出版日期: | 出版商: Market Research Future | 英文 84 Pages | 訂單完成後即時交付

價格

美國東南部的腎臟病市場成長，起因於糖尿病和高血壓的病例增加，慢性腎臟病的盛行率上升。還有美國東南部的老人人口增加和政府的配合措施的高漲也帶來今後的成長機會。

本報告提供美國東南部的腎臟病市場調查，市場定義和概要，市場成長的各種影響因素分析，市場規模的變化、預測，各種區分的明細，競爭環境，主要企業簡介等彙整資訊。

目錄

第1章 摘要整理

第2章 市場概要

第3章 調查手法

第4章 市場動態

  • 概要
  • 促進因素
  • 阻礙因素
  • 威脅
  • 趨勢
  • 腎臟病專門醫生及新畢業者數

第5章 市場要素分析

  • 價值鏈分析
  • 波特的五力分析
  • COVID-19:對市場的影響

第6章 美國東南部的腎臟病市場:各疾病類型

  • 概要
  • 慢性腎臟病
  • 末期腎臟病
  • 其他

第7章 美國東南部的腎臟病市場:各治療類型

  • 概要
  • 透析
  • 投藥
  • 腎臟移植

第8章 美國東南部的腎臟病市場:各終端用戶

  • 概要
  • 透析中心
  • 醫院、診所
  • 研究機關、學術機構
  • 其他

第9章 競爭情形

  • 概要
  • 競爭基準
  • 主要成長策略
  • 在開發數的主要企業
  • 主要的展開的分析
  • 主要的展開、成長策略
  • 財務矩陣

第10章 企業簡介

  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • NOVARTIS AG
  • ABBOTT
  • PFIZER INC.
  • GLAXOSMITHKLINE PLC
  • SANOFI
  • ASTRAZENECA
  • BRISTOL-MYERS SQUIBB COMPANY
  • F. HOFFMANN-LA ROCHE LTD
  • AMGEN INC.
  • FRESENIUS MEDICAL CARE AG & CO.
  • KISSEI PHARMACEUTICAL CO., LTD
  • AKEBIA THERAPEUTICS

第11章 附錄

Product Code: NA

Market Overview

The renal disease affects the body's ability to clean blood and filter extra water. The two main causes of chronic kidney disease are diabetes and high blood pressure, which are responsible for up to two-thirds of the cases. Diabetes happens when your blood sugar is too high, causing damage to many organs in your body, including the kidneys and heart, as well as blood vessels, nerves and eyes. High blood pressure, or hypertension, occurs when the pressure of your blood against the walls of your blood vessels increases. If uncontrolled, or poorly controlled, high blood pressure can be a leading cause of heart attacks, strokes, and chronic kidney disease. Also, chronic kidney disease can cause high blood pressure.

The scope of the Southeast US renal disease market study includes market size analysis and a detailed analysis of the manufacturer's products and service strategies.

Renal or kidney disease is a condition in which the kidneys cannot function properly, remove waste and extra water from the blood or keep body chemicals in balance. Depending upon the numerous conditions, different types of symptoms, and signs, different types of kidney diseases are formed.

The growth of the Southeast US renal disease market is driven by the increasing cases of diabetes and hypertension and the rising prevalence of chronic kidney disease. Additionally, the growing geriatric population in the Southeast US and rise in government initiatives will provide growth opportunities for the market in the future. However, the risks associated with dialysis procedures and kidney transplantation might hamper the growth of the market in the forecast period.

Market Segmentation

The market is segmented in terms of disease type, treatment type and end user.

The Southeast US renal disease market is segmented based on disease type into chronic kidney disease, end-stage renal disease (ESRD), and others. The other segment includes acute kidney injury, kidney cysts, kidney stones, kidney infections, and proteinuria.

The Southeast US renal disease market is segmented based on treatment type into dialysis, medication, and kidney transplantation. The dialysis segment is further sub-segmented into antihypertensive drugs, erythropoiesis-stimulating agents (ESAs), potassium binders, and phosphate binders. The medication segment is further bifurcated into diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers, B blockers, renin inhibitors, vasodilators, and others.

Based on end user, the Southeast US renal disease market is bifurcated into dialysis centers, hospitals & clinics, research and academic institutes, and others. The others segment includes diagnostic centers, home care settings, and others

Major Players

key players contributing to the market growth include Sanofi, Teva Pharmaceuticals, Abbott, GSK, AstraZeneca, Pfizer Inc., Bristol-Myers Squibb Company, Fresenius Medical Care AG & Co. KG F Hoffman-La Roche Ltd, Amgen Inc. Kissie Pharmaceuticals, and Akebia Therapeutics.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 SCOPE OF THE STUDY
  • 2.2 RESEARCH OBJECTIVE
  • 2.3 MARKET STRUCTURE
  • 2.4 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING
  • 3.2 SECONDARY RESEARCH
  • 3.3 PRIMARY RESEARCH
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5 FORECASTING TECHNIQUES
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.6.1 BOTTOM-UP APPROACH
    • 3.6.2 TOP-DOWN APPROACH
  • 3.7 DATA TRIANGULATION
  • 3.8 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 INCREASING CASES OF DIABETES AND HYPERTENSION
    • 4.2.2 RISING PREVALENCE OF CHRONIC KIDNEY DISEASE
  • 4.3 RESTRAINT
    • 4.3.1 RISKS ASSOCIATED WITH DIALYSIS PROCEDURE AND KIDNEY TRANSPLANTATION
  • 4.4 OPPORTUNITIES
    • 4.4.1 GROWING GERIATRIC POPULATION
    • 4.4.2 RISE IN GOVERNMENT INITIATIVES
  • 4.5 THREAT
    • 4.5.1 SUSTAINABILITY OF SMALL AND MEDIUM-SIZED COMPANIES IN THE MARKET
  • 4.6 TREND
    • 4.6.1 TREND OF MEDICAL PRACTICE GROWTH AMONG NEPHROLOGISTS
  • 4.7 NUMBER OF NEPHROLOGISTS CURRENTLY PRACTISING AND NEW GRADUATES GOING INTO THIS SPECIALTY

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 R&D
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION AND SALES
    • 5.1.4 POST-SALES MONITORING
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF BUYERS
    • 5.2.3 THREAT OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTES
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT OF COVID-19 ON THE SOUTHEAST US RENAL DISEASE MARKET
    • 5.3.1 IMPACT ON SUPPLY CHAIN
    • 5.3.2 IMPACT ON ESRD PATIENTS

6 SOUTHEAST US RENAL DISEASE MARKET, BY DISEASE TYPE

  • 6.1 OVERVIEW
  • 6.2 CHRONIC KIDNEY DISEASE
  • 6.3 END-STAGE RENAL DISEASE
  • 6.4 OTHERS

7 SOUTHEAST US RENAL DISEASE MARKET, BY TREATMENT TYPE

  • 7.1 OVERVIEW
  • 7.2 DIALYSIS
  • 7.3 MEDICATION
  • 7.4 KIDNEY TRANSPLANTATION

8 SOUTHEAST US RENAL DISEASE MARKET, BY END USER

  • 8.1 OVERVIEW
  • 8.2 DIALYSIS CENTERS
  • 8.3 HOSPITALS & CLINICS
  • 8.4 RESEARCH AND ACADEMIC INSTITUTES
  • 8.5 OTHERS

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 COMPETITIVE BENCHMARKING
  • 9.3 MAJOR GROWTH STRATEGY IN THE SOUTHEAST US RENAL DISEASE MARKET
  • 9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE SOUTHEAST US RENAL DISEASE MARKET
  • 9.5 KEY DEVELOPMENT ANALYSIS
  • 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
    • 9.6.2 MERGER &ACQUISITION
    • 9.6.3 PARTNERSHIP/AGREEMENT/MARKETING STRATEGY
    • 9.6.4 CLINICAL TRIALS
  • 9.7 FINANCIAL MATRIX
    • 9.7.1 SALES (USD MILLION), 2020
    • 9.7.2 R&D EXPENDITURE (USD MILLION), 2020

10 COMPANY PROFILES

  • 10.1 TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 10.1.1 COMPANY OVERVIEW
    • 10.1.2 FINANCIAL OVERVIEW
    • 10.1.3 PRODUCTS/SERVICES OFFERED
    • 10.1.4 KEY DEVELOPMENTS
    • 10.1.5 SWOT ANALYSIS
    • 10.1.6 KEY STRATEGIES
  • 10.2 NOVARTIS AG
    • 10.2.1 COMPANY OVERVIEW
    • 10.2.2 FINANCIAL OVERVIEW
    • 10.2.3 PRODUCTS/SERVICES OFFERED
    • 10.2.4 KEY DEVELOPMENTS
    • 10.2.5 SWOT ANALYSIS
    • 10.2.6 KEY STRATEGIES
  • 10.3 ABBOTT
    • 10.3.1 COMPANY OVERVIEW
    • 10.3.2 FINANCIAL OVERVIEW
    • 10.3.3 PRODUCTS/SERVICES OFFERED
    • 10.3.4 KEY DEVELOPMENTS
    • 10.3.5 KEY STRATEGIES
  • 10.4 PFIZER INC.
    • 10.4.1 COMPANY OVERVIEW
    • 10.4.2 FINANCIAL OVERVIEW
    • 10.4.3 PRODUCTS/SERVICES OFFERED
    • 10.4.4 KEY DEVELOPMENTS
    • 10.4.5 SWOT ANALYSIS
    • 10.4.6 KEY STRATEGIES
  • 10.5 GLAXOSMITHKLINE PLC
    • 10.5.1 COMPANY OVERVIEW
    • 10.5.2 FINANCIAL OVERVIEW
    • 10.5.3 PRODUCTS/SERVICES OFFERED
    • 10.5.4 KEY DEVELOPMENTS
    • 10.5.5 KEY STRATEGIES
  • 10.6 SANOFI
    • 10.6.1 COMPANY OVERVIEW
    • 10.6.2 FINANCIAL OVERVIEW
    • 10.6.3 PRODUCTS/SERVICES OFFERED
    • 10.6.4 KEY DEVELOPMENTS
    • 10.6.5 SWOT ANALYSIS
    • 10.6.6 KEY STRATEGIES
  • 10.7 ASTRAZENECA
    • 10.7.1 COMPANY OVERVIEW
    • 10.7.2 FINANCIAL OVERVIEW
    • 10.7.3 PRODUCTS/SERVICES OFFERED
    • 10.7.4 KEY DEVELOPMENTS
    • 10.7.5 KEY STRATEGIES
  • 10.8 BRISTOL-MYERS SQUIBB COMPANY
    • 10.8.1 COMPANY OVERVIEW
    • 10.8.2 FINANCIAL OVERVIEW
    • 10.8.3 PRODUCTS/SERVICES OFFERED
    • 10.8.4 KEY DEVELOPMENTS
    • 10.8.5 KEY STRATEGIES
  • 10.9 F. HOFFMANN-LA ROCHE LTD
    • 10.9.1 COMPANY OVERVIEW
    • 10.9.2 FINANCIAL OVERVIEW
    • 10.9.3 PRODUCTS/SERVICES OFFERED
    • 10.9.4 KEY DEVELOPMENTS
    • 10.9.5 KEY STRATEGIES
  • 10.10 AMGEN INC.
    • 10.10.1 COMPANY OVERVIEW
    • 10.10.2 FINANCIAL OVERVIEW
    • 10.10.3 PRODUCTS/SERVICES OFFERED
    • 10.10.4 KEY DEVELOPMENTS
    • 10.10.5 KEY STRATEGIES
  • 10.11 FRESENIUS MEDICAL CARE AG & CO.
    • 10.11.1 COMPANY OVERVIEW
    • 10.11.2 FINANCIAL OVERVIEW
    • 10.11.3 PRODUCTS/SERVICES OFFERED
    • 10.11.4 KEY DEVELOPMENTS
    • 10.11.5 SWOT ANALYSIS
    • 10.11.6 KEY STRATEGIES
  • 10.12 KISSEI PHARMACEUTICAL CO., LTD
    • 10.12.1 COMPANY OVERVIEW
    • 10.12.2 FINANCIAL OVERVIEW
    • 10.12.3 PRODUCTS/SERVICES OFFERED
    • 10.12.4 KEY DEVELOPMENTS
    • 10.12.5 KEY STRATEGIES
  • 10.13 AKEBIA THERAPEUTICS
    • 10.13.1 COMPANY OVERVIEW
    • 10.13.2 FINANCIAL OVERVIEW
    • 10.13.3 PRODUCTS/SERVICES OFFERED
    • 10.13.4 KEY DEVELOPMENTS
    • 10.13.5 KEY STRATEGIES

11 APPENDIX

  • 11.1 REFERENCES
  • 11.2 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • TABLE 3 SOUTHEAST US RENAL DISEASE MARKET, BY DISEASE TYPE, 2018 - 2027 (USD MILLION)
  • TABLE 4 SOUTHEAST US RENAL DISEASE MARKET, BY TREATMENT TYPE, 2018 - 2027 (USD MILLION)
  • TABLE 5 SOUTHEAST US RENAL DISEASE MARKET, FOR MEDICATION BY TYPE, 2018 - 2027 (USD MILLION)
  • TABLE 6 SOUTHEAST US RENAL DISEASE MARKET, FOR ANTIHYPERTENSIVE DRUGS BY TYPE, 2018 - 2027 (USD MILLION)
  • TABLE 7 SOUTHEAST US RENAL DISEASE MARKET, BY END USER, 2018 - 2027 (USD MILLION)
  • TABLE 8 MAJOR PLAYERS IN THE SOUTHEAST US RENAL DISEASE MARKET
  • TABLE 9 MOST ACTIVE PLAYER IN THE SOUTHEAST US RENAL DISEASE MARKET
  • TABLE 10 PRODUCT LAUNCH/PRODUCT APPROVAL
  • TABLE 11 MERGER &ACQUISITION
  • TABLE 12 PARTNERSHIP/AGREEMENT/MARKETING STRATEGY
  • TABLE 13 CLINICAL TRIALS
  • TABLE 14 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 15 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
  • TABLE 16 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 17 NOVARTIS AG: KEY DEVELOPMENTS
  • TABLE 18 ABBOTT: PRODUCTS/SERVICES OFFERED
  • TABLE 19 PFIZER INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 20 PFIZER INC.: KEY DEVELOPMENTS
  • TABLE 21 GLAXOSMITH KLINE PLC: PRODUCTS/SERVICES OFFERED
  • TABLE 22 GLAXOSMITH KLINE PLC.: KEY DEVELOPMENTS
  • TABLE 23 SANOFI: PRODUCTS/SERVICES OFFERED
  • TABLE 24 SANOFI.: KEY DEVELOPMENTS
  • TABLE 25 ASTRAZENECA: PRODUCTS/SERVICES OFFERED
  • TABLE 26 ASTRAZENECA.: KEY DEVELOPMENTS
  • TABLE 27 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED
  • TABLE 28 BRISTOL-MYERS SQUIBB COMPANY.: KEY DEVELOPMENTS
  • TABLE 29 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 30 F. HOFFMANN-LA ROCHE LTD.: KEY DEVELOPMENTS
  • TABLE 31 AMGEN INC.: PRODUCTS/SERVICE OFFERINGS
  • TABLE 32 FRESENIUS MEDICAL CARE AG & CO.: PRODUCTS/SERVICES OFFERED
  • TABLE 33 FRESENIUS MEDICAL CARE AG & CO.: KEY DEVELOPMENTS
  • TABLE 34 KISSEI PHARMACEUTICALS CO., LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 35 AKEBIA THERAPEUTICS.: PRODUCTS/SERVICES OFFERED
  • TABLE 36 AKEBIA THERAPEUTICS: KEY DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 MARKET STRUCTURE: SOUTHEAST US RENAL DISEASE MARKET
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 4 MARKET DYNAMICS: SOUTHEAST US RENAL DISEASE MARKET
  • FIGURE 5 DRIVER IMPACT ANALYSIS
  • FIGURE 6 RESTRAINT: IMPACT ANALYSIS
  • FIGURE 7 NUMBER OF FILLED NEPHROLOGIST FELLOWSHIP POSITIONS, 2010-2020
  • FIGURE 8 ADULT NEPHROLOGY FELLOWS AND YEARS OF TRAINING, 2019
  • FIGURE 9 PEDIATRIC NEPHROLOGY FELLOWS AND YEARS OF TRAINING, 2019
  • FIGURE 10 PERCENTAGE OF FELLOWS BASED ON FELLOWSHIP YEAR, 2018
  • FIGURE 11 NUMBER OF FELLOWS BASED ON ADULT NEPHROLOGY FELLOWSHIP, 2018
  • FIGURE 12 VALUE CHAIN ANALYSIS: SOUTHEAST US RENAL DISEASE MARKET
  • FIGURE 13 PORTER'S FIVE FORCES ANALYSIS: SOUTHEAST US RENAL DISEASE MARKET
  • FIGURE 14 SOUTHEAST US RENAL DISEASE MARKET, BY DISEASE TYPE, 2020 & 2027 (USD MILLION)
  • FIGURE 15 SOUTHEAST US RENAL DISEASE MARKET, BY TREATMENT TYPE, 2020 & 2027 (USD MILLION)
  • FIGURE 16 SOUTHEAST US RENAL DISEASE MARKET, BY END USER, 2020 & 2027 (USD MILLION)
  • FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 18 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE SOUTHEAST US RENAL DISEASE MARKET
  • FIGURE 19 SOUTHEAST US RENAL DISEASE MARKET: COMPETITIVE LANDSCAPE
  • FIGURE 20 SALES (USD MILLION), 2020
  • FIGURE 21 R&D EXPENDITURE (USD MILLION), 2020
  • FIGURE 22 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 23 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
  • FIGURE 24 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 25 NOVARTIS AG: SWOT ANALYSIS
  • FIGURE 26 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 27 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 28 PFIZER INC.: SWOT ANALYSIS
  • FIGURE 29 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 30 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 31 SANOFI: SWOT ANALYSIS
  • FIGURE 32 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 33 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 34 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 35 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 36 FRESENIUS MEDICAL CARE AG & CO.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 37 FRESENIUS MEDICAL CARE AG & CO.: SWOT ANALYSIS
  • FIGURE 38 KISSEI PHARMACEUTICAL CO., LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 39 AKEBIA THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT